Next report date
Report period
Q1 2024
EPS estimate
−0.22USD
Revenue estimate
2.33 MUSD
−1.59USD
−41.97 MUSD
6.77 MUSD
14.12 M
About LAVA Therapeutics N.V.
Sector
Industry
CEO
Stephen Allen Hurly
Website
Headquarters
Utrecht
Employees (FY)
37
Founded
2016
ISIN
NL0015000AG6
FIGI
BBG00L04L545
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of LVTX is 2.64 USD — it has decreased by 3.65% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange LAVA Therapeutics N.V. stocks are traded under the ticker LVTX.
LAVA Therapeutics N.V. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
LVTX stock is 13.10% volatile and has beta coefficient of 0.91. Check out the list of the most volatile stocks — is LAVA Therapeutics N.V. there?
LVTX earnings for the last quarter are −0.34 USD per share, whereas the estimation was −0.49 USD resulting in a 30.61% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about LAVA Therapeutics N.V. earnings.
Yes, you can track LAVA Therapeutics N.V. financials in yearly and quarterly reports right on TradingView.
LVTX stock has fallen by 10.20% compared to the previous week, the month change is a 29.60% fall, over the last year LAVA Therapeutics N.V. has showed a 65.00% increase.
LVTX net income for the last quarter is −6.50 M USD, while the quarter before that showed −8.84 M USD of net income which accounts for 26.46% change. Track more LAVA Therapeutics N.V. financial stats to get the full picture.
Today LAVA Therapeutics N.V. has the market capitalization of 69.40 M, it has decreased by 1.38% over the last week.
No, LVTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LVTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LAVA Therapeutics N.V. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 37.00 employees. See our rating of the largest employees — is LAVA Therapeutics N.V. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LAVA Therapeutics N.V. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LAVA Therapeutics N.V. stock shows the sell signal. See more of LAVA Therapeutics N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on LAVA Therapeutics N.V. future price: according to them, LVTX price has a max estimate of 11.00 USD and a min estimate of 6.00 USD. Read a more detailed LAVA Therapeutics N.V. forecast: see what analysts think of LAVA Therapeutics N.V. and suggest that you do with its stocks.